anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

47,221-47,250 of 319,975

filter-aware
181
This is a standard regulatory disclosure document.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
182
This is a standard legal disclosure page from an ERISA or investment advisory presentation.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
183
This is a standard legal disclosure page, likely part of a larger document set.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
01
Slide 1
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
02
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
03
The slide uses a list of callout boxes to highlight key company milestones and financial status.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
04
The slide uses a timeline-based visualization to show the status of drug development programs.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
05
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
06
The slide uses a horizontal process-like flow to present key metrics.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
07
The slide emphasizes the bioerodible nature and small size of the insert compared to legacy technology.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
08
The slide explains the mechanism of action (Vorolanib) and the delivery technology (Durasert E) for the product DURAVYU.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
09
The slide uses a table-like structure to map clinical trials (DAVIO, DAVIO 2, PAVIA, VERONA) to patient counts and key outcomes.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
10
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
11
The slide uses a four-column layout to present strategic advantages.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
12
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
13
Includes a callout box regarding LUGANO enrollment status.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
14
The slide uses a timeline framework to track trial progress from Jan 2025 to mid-2026.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
15
Includes company logo and copyright information.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
16
The slide uses a timeline-based visual to contrast injection frequency across five different pharmaceutical products.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
17
The slide uses a timeline-based study design framework.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
18
The slide uses a split-layout with a summary/thesis on the left and specific trial results on the right.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
19
The chart compares DURAVYU 2.7mg, 1.3mg, and aflibercept 2mg. A red box highlights the early improvement at Week 4.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
20
The outlier patient missed multiple visits, leading to significant vision loss at week 24.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
21
The chart compares DURAVYU 2.7mg, DURAVYU 1.3mg, and Aflibercept 2mg. The final values at Week 24 are highlighted in a box.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
22
Includes company logo and copyright/disclaimer footer.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
23
Supplement-free is defined as patients who did not receive a supplement at any point during the study.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
24
The slide uses a timeline to show the transition from standard-of-care anti-VEGF injections to the DURAVYU treatment.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
25
The slide uses a timeline to show prior SOC injections followed by the DURAVYU treatment and subsequent follow-up.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
26
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
27
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit